Elexacaftor-d3 (VX-445-d3) is the deuterium labeled form of Elexacaftor, designed as a tracer and internal standard for quantitative analysis using methods like NMR, GC-MS, or LC-MS. Deuterium substitution can impact the pharmacokinetic and metabolic profiles of drugs. Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector, which helps restore Phe508del CFTR protein function and has potential in treating cystic fibrosis. When combined with Tezacaftor and VX-770, it significantly enhances Phe508del CFTR protein processing, trafficking, and chloride transport.
- Tracer and internal standard for quantitative analysis
- Potential to influence pharmacokinetic and metabolic profiles of drugs
- Restores Phe508del CFTR protein function
- Potential to treat cystic fibrosis
- Enhances CFTR protein processing, trafficking, and chloride transport